1. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication‐overuse headache: Subgroup analysis of PROMISE‐2. Issue 1 (13th December 2020) Authors: Diener, Hans‐Christoph; Marmura, Michael J.; Tepper, Stewart J.; Cowan, Robert; Starling, Amaal J.; Diamond, Merle L.; Hirman, Joe; Mehta, Lahar; Brevig, Thomas; Sperling, Bjørn; Cady, Roger Journal: Headache Issue: Volume 61:Issue 1(2021) Page Start: 125 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache. Issue 9 (22nd September 2021) Authors: Marmura, Michael J.; Diener, Hans‐Christoph; Cowan, Robert P.; Tepper, Stewart J.; Diamond, Merle L.; Starling, Amaal J.; Hirman, Joe; Mehta, Lahar; Brevig, Thomas; Cady, Roger Journal: Headache Issue: Volume 61:Issue 9(2021) Page Start: 1421 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗